Update on the biology and treatment options for hairy cell leukemia

Current Treatment Options in Oncology

Volumn 15, Issue 2, 2014, Pages 187-209

  Jain, Preetesh ^a   Pemmaraju, Naveen ^a   Ravandi, Farhad ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

BRAF mutations; Cladribine; Hairy cell leukemia; Immunotoxins; Pentostatin; Rituximab; Vemurafenib

Indexed keywords

ALPHA INTERFERON; BASILIXIMAB; BENDAMUSTINE; CLADRIBINE; DABRAFENIB; FLAVOPIRIDOL; FLUDARABINE; HEMOGLOBIN; IBRUTINIB; INTERLEUKIN 1 RECEPTOR; MOXETUMOMAB PASUDOTOX; PENTOSTATIN; PURINE DERIVATIVE; RITUXIMAB; SELUMETINIB; TRAMETINIB; VEMURAFENIB; ANTINEOPLASTIC AGENT; B RAF KINASE; BRAF PROTEIN, HUMAN; CD20 ANTIGEN; IMMUNOTOXIN; INDOLE DERIVATIVE; MONOCLONAL ANTIBODY; RECOMBINANT PROTEIN; SULFONAMIDE;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; ARTICLE; B LYMPHOCYTE; BLOOD CELL COUNT; BONE MARROW BIOPSY; BRAF GENE; CANCER SURVIVAL; CELL HOMING; CELLULAR DISTRIBUTION; CENTRAL NERVOUS SYSTEM DISEASE; CHROMOSOME ABERRATION; CLINICAL FEATURE; CONTINUOUS INFUSION; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DEPRESSION; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG RESPONSE; FATIGUE; FLOW CYTOMETRY; FLU LIKE SYNDROME; GENE; GENE MUTATION; HAIRY CELL LEUKEMIA; HEMOGLOBIN BLOOD LEVEL; HEMOLYTIC UREMIC SYNDROME; HISTOPATHOLOGY; HUMAN; IGHV GENE; IMMUNOPHENOTYPING; LEUKOCYTOSIS; LYMPHADENOPATHY; MANTLE CELL LYMPHOMA; MONOCYTOPENIA; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PANCYTOPENIA; PATHOPHYSIOLOGY; RECURRENCE FREE SURVIVAL; RECURRENT INFECTION; SECOND CANCER; SIGNAL TRANSDUCTION; SPLENECTOMY; SPLENOMEGALY; THROMBOCYTOPENIA; TP53 GENE; TUMOR LYSIS SYNDROME; TUMOR MICROENVIRONMENT; GENETICS; IMMUNOLOGY; LEUKEMIA, HAIRY CELL; MUTATION; RECURRENT DISEASE;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; B-LYMPHOCYTES; CLADRIBINE; DISEASE-FREE SURVIVAL; HUMANS; IMMUNOPHENOTYPING; IMMUNOTOXINS; INDOLES; LEUKEMIA, HAIRY CELL; MUTATION; PENTOSTATIN; PROTO-ONCOGENE PROTEINS B-RAF; RECOMBINANT PROTEINS; RECURRENCE; SULFONAMIDES;

EID: 84902364139     PISSN: 15272729     EISSN: 15346277     Source Type: Journal    
DOI: 10.1007/s11864-014-0285-5     Document Type: Article

References (131)

1. Bouroncle BA, Wiseman BK, Doan CA. Leukemic reticuloendotheliosis. Blood. 1958;13(7):609-30.
2. Schrek R, Donnelly WJ. "Hairy" cells in blood in lymphoreticular neoplastic disease and "flagellated"cells of normal lymph nodes. Blood. 1966;27(2):199-211.
3. Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011;117(19):5019-32. doi:10.1182/blood-2011-01- 293050.
4. Chandran R, Gardiner SK, Smith SD, Spurgeon SE. Improved survival in hairy cell leukaemia over three decades: a SEER database analysis of prognostic factors. Brit J Haematol. 2013;163(3):407-9. doi:10.1111/bjh.12490.
5. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA: Cancer J Clin. 2013;63(1):11-30. doi:10.3322/caac.21166.
6. Kilbridge TM, Kadin ME. Teenager with hairy cell leukemia: 30-year follow-up. J Clin Oncol: Off J Am Soc Clin Oncol. 2009;27(1):155-6. doi:10.1200/JCO.2008.20.3372.
7. Paltiel O, Adler B, Barchana M, Dann EJ. A population-based study of hairy cell leukemia in Israel. Eur J Haematol. 2006;77(5):372-7. doi:10.1111/j.1600-0609.2006.00732.x. (Pubitemid 44483939)
8. Dores GM, Matsuno RK, Weisenburger DD, Rosenberg PS, Anderson WF. Hairy cell leukaemia: a heterogeneous disease? Brit J Haematol. 2008;142(1):45-51. doi:10.1111/j.1365-2141.2008.07156.x. (Pubitemid 351783152)
9. Colovic MD, Jankovic GM, Wiernik PH. Hairy cell leukemia in first cousins and review of the literature. Eur J Haematol. 2001;67(3):185-8. (Pubitemid 33105059)
10. Goldin LR, Bjorkholm M, Kristinsson SY, Turesson I, Landgren O. Elevated risk of chronic lymphocytic leukemia and other indolent non-Hodgkin's lymphomas among relatives of patients with chronic lymphocytic leukemia. Haematologica. 2009;94(5):647-53. doi:10.3324/haematol.2008.003632.
11. Rumi E, Passamonti F, Zibellini S, Martinetti M, Arcaini L, Elena C, et al. HLA typing and VH gene rearrangement analysis in a family with hairy cell leukaemia. Leuk Lymphoma. 2007;48(4):805-7. doi:10.1080/10428190601158654. (Pubitemid 46605555)
12. Anderson LA, Engels EA. Autoimmune conditions and hairy cell leukemia: an exploratory case-control study. J Hematol Oncol. 2010;3:35. doi:10.1186/1756-8722-3-35.
13. Hasler P, Kistler H, Gerber H. Vasculitides in hairy cell leukemia. Sem Arthritis Rheum. 1995;25(2):134-42.
14. Aristeguieta C, de Perio MA. Three cases of hairy cell leukemia in coal miners. Leuk Lymphoma. 2011;52(12):2391-2. doi:10.3109/10428194.2011.610011.
15. • Kamiguti AS, Harris RJ, Slupsky JR, Baker PK, Cawley JC, Zuzel M. Regulation of hairy-cell survival through constitutive activation of mitogenactivated protein kinase pathways. Oncogene. 2003;22(15):2272-84. doi:10.1038/sj.onc.1206398. Initial study showing the significance of MAP kinase pathway in the survival of HCL cells.
16. Nicolaou F, Teodoridis JM, Park H, Georgakis A, Farokhzad OC, Bottinger EP, et al. CD11c gene expression in hairy cell leukemia is dependent upon activation of the proto-oncogenes ras and junD. Blood. 2003;101(10):4033-41. doi:10.1182/blood-2002-01-0324. (Pubitemid 36857883)
17. .•• Tiacci E, Trifonov V, Schiavoni G, Holmes A, Kern W, Martelli MP, et al. BRAF mutations in hairy-cell leukemia. N Engl J Med. 2011;364(24):2305-15. doi:10.1056/NEJMoa1014209. Pivotal study which demonstrated that BRAF mutations (V600E) is universally present in all patients with classical HCL and are responsible for HCL cell growth and survival.
18. Park JH, Kim E, Chung YR, Hu W, Lito P, Feldstein JT, et al. BRAFV600E Mutations Occur In The Hematopoietic Stem Cell Compartment In Hairy Cell Leukemia. Blood. 2013;122(21):816.
19. .• Xi L, Arons E, Navarro W, Calvo KR, Stetler-Stevenson M, Raffeld M, et al. Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation. Blood. 2012;119(14):3330-2. doi:10.1182/blood-2011-09-379339. First study to demonstrate that BRAF mutations are not seen in variant HCL and VH4-34 molecular variant of HCL.
20. Arcaini L, Zibellini S, Boveri E, Riboni R, Rattotti S, Varettoni M, et al. The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms. Blood. 2012;119(1):188-91. doi:10.1182/blood-2011-08-368209.
21. Tiacci E, Schiavoni G, Martelli MP, Boveri E, Pacini R, Tabarrini A, et al. Constant activation of the RAF-MEK-ERK pathway as a diagnostic and therapeutic target in hairy cell leukemia. Haematologica. 2013;98(4):635-9. doi:10.3324/haematol.2012.078071.
22. Boyd EM, Bench AJ, van Veer MB, Wright P, Bloxham DM, Follows GA, et al. High resolution melting analysis for detection of BRAF exon 15 mutations in hairy cell leukaemia and other lymphoid malignancies. Brit J Haematol. 2011;155(5):609-12. doi:10.1111/j.1365-2141.2011.08868.x.
23. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949-54. doi:10.1038/nature00766. (Pubitemid 34716871)
24. Tiacci E. Schiavoni G. Boveri E, Pacini R, Tabarrini A et al. Constant activation of the RAF-MEK-ERK pathway as a diagnostic and therapeutic target in hairy cell leukemia. Haematologica: Martelli MP; 2013. doi:10.3324/haematol. 2012.078071.
25. Verma S, Greaves WO, Ravandi F, Reddy N, Bueso-Ramos CE, O'Brien S, et al. Rapid detection and quantitation of BRAF mutations in hairy cell leukemia using a sensitive pyrosequencing assay. Am J Clin Pathol. 2012;138(1):153-6. doi:10.1309/AJCPL0OPXI9LZITV.
26. Laurini JA, Aoun P, Iqbal J, Chan W, Greiner TC. Investigation of the BRAF V600E mutation by pyro-sequencing in lymphoproliferative disorders. Am J Clin Pathol. 2012;138(6):877-83. doi:10.1309/AJCP5TWORA0TMXGL.
27. Munoz J, Schlette E, Kurzrock R. Rapid response to vemurafenib in a heavily pretreated patient with hairy cell leukemia and a BRAF mutation. J Clin Oncol: Off J Am Soc Clin Oncol. 2013;31(20):e351-2. doi:10.1200/JCO.2012.45. 7739.
28. Peyrade F, Re D, Ginet C, Gastaud L, Allegra M, Ballotti R, et al. Low-dose vemurafenib induces complete remission in a case of hairy-cell leukemia with a V600E mutation. Haematologica. 2013;98(2):e20-2. doi:10.3324/haematol. 2012.082404.
29. Follows GA, Sims H, Bloxham DM, Zenz T, Hopper MA, Liu H, et al. Rapid response of biallelic BRAF V600E mutated hairy cell leukaemia to low dose vemurafenib. Brit J Haematol. 2013;161(1):150-3. doi:10.1111/bjh.12201.
30. Dietrich S, Glimm H, Andrulis M, von Kalle C, Ho AD, Zenz T. BRAF inhibition in refractory hairy-cell leukemia. N Engl J Med. 2012;366(21):2038- 40. doi:10.1056/NEJMc1202124.
31. Chung SS, Chung YR, Won H, Teruya-Feldstein J, Berger M, Khawaja TT, et al. Phase II Trial Of The BRAF Inhibitor, Vemurafenib, In Patients With BRAF Mutant Relapsed Or Refractory Hairy Cell Leukemia. Blood. 2013;122(21):2876.
32. Lito P, Rosen N, Solit DB. Tumor adaptation and resistance to RAF inhibitors. Nat Med. 2013;19(11):1401-9. doi:10.1038/nm.3392.
33. Waterfall JJ, Arons E, Walker RL, Pineda M, Roth L, Killian JK, et al. High prevalence of MAP2K1 mutations in variant and IGHV4-34-expressing hairy-cell leukemias. Nat Genet. 2014;46(1):8-10. doi:10.1038/ng.2828.
34. Vanhentenrijk V, Tierens A, Wlodarska I, Verhoef G, Wolf-Peeters CD. V(H) gene analysis of hairy cell leukemia reveals a homogeneous mutation status and suggests its marginal zone B-cell origin. Leukemia. 2004;18(10):1729-32. doi:10.1038/sj.leu.2403503. (Pubitemid 39386355)
35. Miranda RN, Cousar JB, Hammer RD, Collins RD, Vnencak-Jones CL. Somatic mutation analysis of IgH variable regions reveals that tumor cells of most parafollicular (monocytoid) B-cell lymphoma, splenic marginal zone B-cell lymphoma, and some hairy cell leukemia are composed of memory B lymphocytes. Hum Pathol. 1999;30(3):306-12. (Pubitemid 29125151)
36. Basso K, Liso A, Tiacci E, Benedetti R, Pulsoni A, Foa R, et al. Gene expression profiling of hairy cell leukemia reveals a phenotype related to memory B cells with altered expression of chemokine and adhesion receptors. J Exp Med. 2004;199(1):59-68. doi:10.1084/jem.20031175. (Pubitemid 38076478)
37. Vanhentenrijk V, De Wolf-Peeters C, Wlodarska I. Belgian Programme of Interuniversity Poles of A. Comparative expressed sequence hybridization studies of hairy cell leukemia show uniform expression profile and imprint of spleen signature. Blood. 2004;104(1):250-5. doi:10.1182/blood-2004-01-0181. (Pubitemid 38879865)
38. Forconi F, Sahota SS, Raspadori D, Ippoliti M, Babbage G, Lauria F, et al. Hairy cell leukemia: at the crossroad of somatic mutation and isotype switch. Blood. 2004;104(10):3312-7. doi:10.1182/blood-2004-03-0950. (Pubitemid 39507151)
39. Forconi F, Sozzi E, Cencini E, Zaja F, Intermesoli T, Stelitano C, et al. Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior. Blood. 2009;114(21):4696-702. doi:10.1182/blood-2009-03-212449.
40. Rickert RC. New insights into pre-BCR and BCR signalling with relevance to B cell malignancies. Nat Rev Immunol. 2013;13(8):578-91. doi:10.1038/nri3487.
41. Forconi F, Sahota SS, Raspadori D, Mockridge CI, Lauria F, Stevenson FK. Tumor cells of hairy cell leukemia express multiple clonally related immunoglobulin isotypes via RNA splicing. Blood. 2001;98(4):1174-81.
42. Kluin-Nelemans HC, Krouwels MM, Jansen JH, Dijkstra K, van Tol MJ, den Ottolander GJ, et al. Hairy cell leukemia preferentially expresses the IgG3-subclass. Blood. 1990;75(4):972-5. (Pubitemid 20067198)
43. Sambani C, Trafalis DT, Mitsoulis-Mentzikoff C, Poulakidas E, Makropoulos V, Pantelias GE, et al. Clonal chromosome rearrangements in hairy cell leukemia: personal experience and review of literature. Cancer Genet Cytogenet. 2001;129(2):138-44. (Pubitemid 32826306)
44. Dierlamm J, Stefanova M, Wlodarska I, Michaux L, Hinz K, Penas EM, et al. Chromosomal gains and losses are uncommon in hairy cell leukemia: a study based on comparative genomic hybridization and interphase fluorescence in situ hybridization. Cancer Genet Cytogenet. 2001;128(2):164-7. (Pubitemid 32706592)
45. Wu X, Ivanova G, Merup M, Jansson M, Stellan B, Grander D, et al. Molecular analysis of the human chromosome 5q13.3 region in patients with hairy cell leukemia and identification of tumor suppressor gene candidates. Genomics. 1999;60(2):161-71. (Pubitemid 29463674)
46. Hockley SL, Morgan GJ, Leone PE, Walker BA, Morilla A, Else M, et al. High-resolution genomic profiling in hairy cell leukemia-variant compared with typical hairy cell leukemia. Leukemia. 2011;25(7):1189-92. doi:10.1038/leu.2011. 47.
47. Gruber G, Schwarzmeier JD, Shehata M, Hilgarth M, Berger R. Basic fibroblast growth factor is expressed by CD19/CD11c-positive cells in hairy cell leukemia. Blood. 1999;94(3):1077-85. (Pubitemid 29361841)
48. Zhang X, Machii T, Matsumura I, Ezoe S, Kawasaki A, Tanaka H, et al. Constitutively activated Rho guanosine triphosphatases regulate the growth and morphology of hairy cell leukemia cells. Int J Hematol. 2003;77(3):263-73. (Pubitemid 37121853)
49. Burger JA, Ghia P, Rosenwald A, Caligaris-Cappio F. The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood. 2009;114(16):3367-75. doi:10.1182/blood-2009-06-225326.
50. Jain P, Javdan M, Feger FK, Chiu PY, Sison C, Damle RN, et al. Th17 and non-Th17 interleukin-17-expressing cells in chronic lymphocytic leukemia: delineation, distribution, and clinical relevance. Haematologica. 2012;97(4):599-607. doi:10.3324/haematol.2011.047316.
51. • Wong S, Fulcher D. Chemokine receptor expression in B-cell lymphoproliferative disorders. Leuk Lymphoma. 2004;45(12):2491-6. doi:10.1080/10428190410001723449. This study demonstrated that HCL cells lack CXCR5 and CCR7 which may explain why HCL cells do not accumulate in lymph nodes.
52. Vincent AM, BurthemJ, BrewR, Cawley JC. Endothelial interactions of hairy cells: the importance of alpha 4 beta 1 in the unusual tissue distribution of the disorder. Blood. 1996;88(10):3945-52. (Pubitemid 26383119)
53. Burthem J, Baker PK, Hunt JA, Cawley JC. Hairy cell interactions with extracellular matrix: expression of specific integrin receptors and their role in the cell's response to specific adhesive proteins. Blood. 1994;84(3):873-82. (Pubitemid 24223885)
54. Aziz KA, Till KJ, Zuzel M, Cawley JC. Involvement of CD44-hyaluronan interaction in malignant cell homing and fibronectin synthesis in hairy cell leukemia. Blood. 2000;96(9):3161-7.
55. Burthem J, Cawley JC. The bone marrow fibrosis of hairy-cell leukemia is caused by the synthesis and assembly of a fibronectin matrix by the hairy cells. Blood. 1994;83(2):497-504. (Pubitemid 24030577)
56. Shehata M, Schwarzmeier JD, Hilgarth M, Hubmann R, Duechler M, Gisslinger H. TGF-beta1 induces bone marrow reticulin fibrosis in hairy cell leukemia. J Clin Investig. 2004;113(5):676-85. doi:10.1172/JCI19540. (Pubitemid 38544160)
57. Pillai V, Pozdnyakova O, Charest K, Li B, Shahsafaei A, Dorfman DM. CD200 flow cytometric assessment and semiquantitative immunohistochemical staining distinguishes hairy cell leukemia from hairy cell leukemia-variant and other B-cell lymphoproliferative disorders. Am J Clin Pathol. 2013;140(4):536-43. doi:10.1309/AJCPEBK31VQQNDDR.
58. Kotsianidis I, Nakou E, Spanoudakis E, Bouchliou I, Moustakidis E, Miltiades P, et al. The diagnostic value of CD1d expression in a large cohort of patients with B-cell chronic lymphoproliferative disorders. Am J Clin Pathol. 2011;136(3):400-8. doi:10.1309/AJCP2F2DOXOTXHZA.
59. Falini B, Tiacci E, Liso A, Basso K, Sabattini E, Pacini R, et al. Simple diagnostic assay for hairy cell leukaemia by immunocytochemical detection of annexin A1 (ANXA1). Lancet. 2004;363(9424):1869-70. doi:10.1016/S0140-6736(04) 16356-3.
60. Bosch F, Campo E, Jares P, Pittaluga S, Munoz J, Nayach I, et al. Increased expression of the PRAD-1/CCND1 gene in hairy cell leukaemia. Brit J Haematol. 1995;91(4):1025-30.
61. van de Corput L, Falkenburg JH, Kester MG, Willemze R, Kluin-Nelemans JC. Impaired expression of CD28 on T cells in hairy cell leukemia. Clin Immunol. 1999;93(3):256-62. doi:10.1006/clim.1999.4794.
62. Spaenij-Dekking EH, Van der Meijden ED, Falkenburg JH, Kluin-Nelemans JC. Clonally expanded T cells in hairy cell leukemia patients are not leukemia specific. Leukemia. 2004;18(1):176-8. doi:10.1038/sj.leu.2403149. (Pubitemid 38165268)
63. Spaenij-Dekking EH, Van Delft J, Van Der Meijden E, Hiemstra HS, Falkenburg JH, Koning F, et al. Synaptojanin 2 is recognized by HLA class II-restricted hairy cell leukemia-specific T cells. Leukemia. 2003;17(12):2467-73. doi:10.1038/sj.leu.2403174. (Pubitemid 38072586)
64. Barak V, Nisman B, Polliack A, Vannier E, Dinarello CA. Correlation of serum levels of interleukin-1 family members with disease activity and response to treatment in hairy cell leukemia. Eur Cytokine Netw. 1998;9(1):33-9. (Pubitemid 28230181)
65. Semenzato G, Trentin L, Zambello R, Agostini C, Bulian P, Siviero F, et al. Origin of the soluble interleukin-2 receptor in the serum of patients with hairy cell leukemia. Leukemia. 1988;2(12):788-92. (Pubitemid 19017104)
66. Baker PK, Pettitt AR, Slupsky JR, Chen HJ, Glenn MA, Zuzel M, et al. Response of hairy cells to IFN-alpha involves induction of apoptosis through autocrine TNF-alpha and protection by adhesion. Blood. 2002;100(2):647-53. (Pubitemid 34761131)
67. Burger JA, Sivina M, Ravandi F. The microenvironment in hairy cell leukemia: pathways and potential therapeutic targets. Leuk Lymphoma. 2011;52 Suppl 2:94-8. doi:10.3109/10428194.2011.568649.
68. Polliack A, Tadmor T. Surface topography of hairy cell leukemia cells compared to other leukemias as seen by scanning electron microscopy. Leuk Lymphoma. 2011;52 Suppl 2:14-7. doi:10.3109/10428194.2011.565095.
69. Miyoshi EK, Stewart PL, Kincade PW, Lee MB, Thompson AA, Wall R. Aberrant expression and localization of the cytoskeleton-binding pp 52 (LSP1) protein in hairy cell leukemia. Leuk Res. 2001;25(1):57-67. (Pubitemid 32012982)
70. Chaigne-Delalande B, Deuve L, Reuzeau E, Basoni C, Lafarge D, Varon C, et al. RhoGTPases and p53 are involved in the morphological appearance and interferon-alpha response of hairy cells. Am J Pathol. 2006;168(2):562-73. (Pubitemid 43271154)
71. Mercieca J, Puga M, Matutes E, Moskovic E, Salim S, Catovsky D. Incidence and significance of abdominal lymphadenopathy in hairy cell leukaemia. Leuk Lymphoma. 1994;14 Suppl 1:79-83. (Pubitemid 24282598)
72. Gray MT, Rutherford MN, Bonin DM, Patterson B, Lopez PG. Hairy-cell leukemia presenting as lytic bone lesions. J Clin Oncol: Off J Am Soc Clin Oncol. 2013;31(25):e410-2. doi:10.1200/JCO.2012.47.5301.
73. Leung R, Lopes D, Lam C, Wong KF, Kung AW, Kwong YL. Diffuse osteosclerosis complicating hairy cell leukemia. J Clin Oncol: Off J Am Soc Clin Oncol. 2010;28(13):e203-4. doi:10.1200/JCO.2009.24.7601.
74. Tadmor T, Polliack A. Unusual clinical manifestations, rare sites of involvement, and the association of other disorders with hairy cell leukemia. Leuk Lymphoma. 2011;52 Suppl 2:57-61. doi:10.3109/10428194.2011.565395.
75. Dasanu CA, Alexandrescu DT. Risk of additional cancers in untreated and treated hairy cell leukemia patients. Expert Opin Pharmacother. 2010;11(1):41-50. doi:10.1517/14656560903405647.
76. Hisada M, Chen BE, Jaffe ES, Travis LB. Second cancer incidence and cause-specific mortality among 3104 patients with hairy cell leukemia: a population-based study. J Natl Cancer Inst. 2007;99(3):215-22. doi:10.1093/jnci/djk030.
77. .• Else M, Dearden CE, Matutes E, Garcia-Talavera J, Rohatiner AZ, Johnson SA, et al. Long-term followup of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Brit J Haematol. 2009;145(6):733-40. doi:10.1111/j.1365-2141.2009. 07668.x. Largest study with long follow up data demonstrating the retrospective data on pentostatin and cladribine in 233 patients.
78. Goodman GR, Burian C, Koziol JA, Saven A. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J Clin Oncol: Off J Am Soc Clin Oncol. 2003;21(5):891-6. (Pubitemid 46606450)
79. .• Arons E, Suntum T, Stetler-Stevenson M, Kreitman RJ. VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy. Blood. 2009;114(21):4687-95. doi:10.1182/blood-2009-01-201731. This study recognized the clinical relevance of assessing VH gene usage in patients with HCL and identified that despite immunophenotypic similarity with classic HCL, VH4-34 variant have poor prognosis.
80. Sigal DS, Sharpe R, Burian C, Saven A. Very long-term eradication of minimal residual disease in patients with hairy cell leukemia after a single course of cladribine. Blood. 2010;115(10):1893-6. doi:10.1182/blood-2009-10- 251645.
81. Matutes E. Immunophenotyping and differential diagnosis of hairy cell leukemia. Hematol/Oncol Clin N Am. 2006;20(5):1051-63. doi:10.1016/j.hoc.2006. 06.012.
82. Matutes E, Morilla R, Owusu-Ankomah K, Houliham A, Meeus P, Catovsky D. The immunophenotype of hairy cell leukemia (HCL). Proposal for a scoring system to distinguish HCL from B-cell disorders with hairy or villous lymphocytes. Leuk Lymphoma. 1994;14 Suppl 1:57-61. (Pubitemid 24282594)
83. Aziz KA, Till KJ, Chen H, Slupsky JR, Campbell F, Cawley JC, et al. The role of autocrine FGF-2 in the distinctive bone marrow fibrosis of hairy-cell leukemia (HCL). Blood. 2003;102(3):1051-6. doi:10.1182/blood-2002-12-3737. (Pubitemid 36917803)
84. Okon K, Szumera A, Papla B, Pietkun I, Zdunczyk A, Rucinska M, et al. Morphometric classification of hairy cell leukemia in bone marrow trephine biopsy. Anal Quant Cytol Histol Int Acad Cytol Am Soc Cytol. 2003;25(4):227-34. (Pubitemid 36994819)
85. Mori N, Murakami YI, Shimada S, Iwamizu-Watanabe S, Yamashita Y, Hasegawa Y, et al. TIA-1 expression in hairy cell leukemia. Mod Pathol: Off J U S A Can Acad Pathol Inc. 2004;17(7):840-6. doi:10.1038/modpathol.3800129. (Pubitemid 38843367)
86. Johrens K, Stein H, Anagnostopoulos I. T-bet transcription factor detection facilitates the diagnosis of minimal hairy cell leukemia infiltrates in bone marrow trephines. Am J Surg Pathol. 2007;31(8):1181-5. doi:10.1097/PAS.0b013e318031045b. (Pubitemid 47207120)
87. Nanba K, Soban EJ, Bowling MC, Berard CW. Splenic pseudosinuses and hepatic angiomatous lesions. Distinctive features of hairy cell leukemia. Am J Clin Pathol. 1977;67(5):415-26. (Pubitemid 8107839)
88. Noel P. Definition of remission, minimal residual disease, and relapse in hairy cell leukemia bone marrow biopsy histology and immunohistology specimens. Leuk Lymphoma. 2011;52 Suppl 2:62-4. doi:10.3109/10428194.2011.565098.
89. Tallman MS, Hakimian D, Kopecky KJ, Wheaton S, Wollins E, Foucar K, et al. Minimal residual disease in patients with hairy cell leukemia in complete remission treated with 2-chlorodeoxyadenosine or 2-deoxycoformycin and prediction of early relapse. Clin Cancer Res: Off J Am Assoc Cancer Res. 1999;5(7):1665-70. (Pubitemid 29334443)
90. Mhawech-Fauceglia P, Oberholzer M, Aschenafi S, Baur A, Kurrer M, Von Rohr A, et al. Potential predictive patterns of minimal residual disease detected by immunohistochemistry on bone marrow biopsy specimens during a long-term follow-up in patients treated with cladribine for hairy cell leukemia. Arch Pathol Lab Med. 2006;130(3):374-7. doi:10.1043/1543-2165(2006)130[374: PPPOMR]2.0.CO;2.
91. .•• Ravandi F, O'Brien S, Jorgensen J, Pierce S, Faderl S, Ferrajoli A, et al. Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia. Blood. 2011;118(14):3818-23. doi:10.1182/blood-2011-04-351502. First study to demonstrate that addition of rituximab to cladribine is safe and effective in the frontline setting and can help to achieve MRD-negative remissions.
92. Else M, Dearden CE, Matutes E, Forconi F, Lauria F, Ahmad H, et al. Rituximab with pentostatin or cladribine: an effective combination treatment for hairy cell leukemia after disease recurrence. Leuk Lymphoma. 2011;52 Suppl 2:75-8. doi:10.3109/10428194.2011.568650.
93. Spiers AS, Moore D, Cassileth PA, Harrington DP, Cummings FJ, Neiman RS, et al. Remissions in hairycell leukemia with pentostatin (2′- deoxycoformycin). N Engl J Med. 1987;316(14):825-30. doi:10.1056/ NEJM198704023161401. (Pubitemid 17056319)
94. .• Grever M, Kopecky K, Foucar MK, Head D, Bennett JM, Hutchison RE, et al. Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study. J Clin Oncol: Off J Am Soc Clin Oncol. 1995;13(4):974-82. First randomized study to demonstrate the superiority of pentostatin over interferon.
95. •• Piro LD, Carrera CJ, Carson DA, Beutler E. Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med. 1990;322(16):1117-21. doi:10.1056/ NEJM199004193221605. This study demonstrated the significant efficacy of single dose of cladribine in patients with HCL.
96. Spiers AS, Parekh SJ, Bishop MB. Hairy-cell leukemia: induction of complete remission with pentostatin (2′-deoxycoformycin). J Clin Oncol: Off J Am Soc Clin Oncol. 1984;2(12):1336-42. (Pubitemid 15179534)
97. Gerrie AS, Zypchen LN, Connors JM. Fludarabine and rituximab for relapsed or refractory hairy cell leukemia. Blood. 2012;119(9):1988-91. doi:10.1182/blood-2011-08-371989.
98. Johnston JB. Mechanism of action of pentostatin and cladribine in hairy cell leukemia. Leuk Lymphoma. 2011;52 Suppl 2:43-5. doi:10.3109/10428194.2011. 570394.
99. Flinn IW, Kopecky KJ, Foucar MK, Head D, Bennett JM, Hutchison R, et al. Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin. Blood. 2000;96(9):2981-6.
100. Seymour JF, Talpaz M, Kurzrock R. Response duration and recovery of CD4+ lymphocytes following deoxycoformycin in interferon-alpha-resistant hairy cell leukemia: 7-year follow-up. Leukemia. 1997;11(1):42-7. (Pubitemid 27065048)
101. Saven A, Burian C, Koziol JA, Piro LD. Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood. 1998;92(6):1918-26. (Pubitemid 28446680)
102. Rosenberg JD, Burian C, Waalen J. Saven A. A Single Institution Series. Blood: Clinical Characteristics and Long-Term Outcome of Young Hairy Cell Leukemia Patients Treated With Cladribine; 2013. doi:10.1182/blood-2013-06- 508754.
103. Jehn U, Bartl R, Dietzfelbinger H, Haferlach T, Heinemann V. An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine. Leukemia. 2004;18(9):1476-81. doi:10.1038/sj.leu. 2403418. (Pubitemid 39264069)
104. Chadha P, Rademaker AW, Mendiratta P, Kim B, Evanchuk DM, Hakimian D, et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience. Blood. 2005;106(1):241-6. doi:10.1182/blood-2005-01-0173. (Pubitemid 40967199)
105. Saven A, Burian C, Adusumalli J, Koziol JA. Filgrastim for cladribine-induced neutropenic fever in patients with hairy cell leukemia. Blood. 1999;93(8):2471-7. (Pubitemid 29181177)
106. Robak T, Blasinska-Morawiec M, Krykowski E, Hansz J, Komarnicki M, Kazimierczak M, et al. 2-chlorodeoxyadenosine (2-CdA) in 2-hour versus 24-hour intravenous infusion in the treatment of patients with hairy cell leukemia. Leuk Lymphoma. 1996;22(1-2):107-11. doi:10.3109/10428199609051736. (Pubitemid 26177726)
107. Robak T, Jamroziak K, Gora-Tybor J, Blonski JZ, Kasznicki M, Dwilewicz-Trojaczek J, et al. Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report fromthe Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial. Blood. 2007;109(9):3672-5. doi:10.1182/blood-2006-08-042929. (Pubitemid 46641714)
108. Zinzani PL, Pellegrini C, Stefoni V, Derenzini E, Gandolfi L, Broccoli A, et al. Hairy cell leukemia: evaluation of the long-term outcome in 121 patients. Cancer. 2010;116(20):4788-92. doi:10.1002/cncr.25243.
109. Nieva J, Bethel K, Saven A. Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia. Blood. 2003;102(3):810-3. doi:10.1182/blood-2003-01-0014. (Pubitemid 36917768)
110. Thomas DA, O'Brien S, Bueso-Ramos C, Faderl S, Keating MJ, Giles FJ, et al. Rituximab in relapsed or refractory hairy cell leukemia. Blood. 2003;102(12):3906-11. doi:10.1182/blood-2003-02-0630. (Pubitemid 37486969)
111. Byrd JC, Rai K, Peterson BL, Appelbaum FR, Morrison VA, Kolitz JE, et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood. 2005;105(1):49-53. doi:10.1182/blood-2004-03-0796.
112. Kreitman RJ, Arons E, Stetler-Stevenson M, Miller KB. Response of hairy cell leukemia to bendamustine. Leuk Lymphoma. 2011;52(6):1153-6. doi:10.3109/10428194.2011.562575.
113. Burotto M, Stetler-Stevenson M, Arons E, Zhou H, Wilson W, Kreitman RJ. Bendamustine and rituximab in relapsed and refractory hairy cell leukemia. Clin Cancer Res: Off J Am Assoc Cancer Res. 2013;19(22):6313-21. doi:10.1158/1078- 0432.CCR-13-1848.
114. Santi A, Russo G, Pucciarini A, Bigerna B, Fortini E, Imperi E, et al. Targeting The BRAF-MEK-ERK Pathway In Hairy Cell Leukemia. Blood. 2013;122(21):3064.
115. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507-16. doi:10.1056/NEJMoa1103782.
116. Samuel J, Macip S, Dyer MJ. Efficacy of vemurafenib in hairy-cell leukemia. N Engl J Med. 2014;370(3):286-8. doi:10.1056/NEJMc1310849.
117. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, openlabel, phase 3 randomised controlled trial. Lancet. 2012;380(9839):358-65. doi:10.1016/S0140-6736(12)60868-X.
118. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367(18):1694-703. doi:10.1056/NEJMoa1210093.
119. Kreitman RJ. Getting plant toxins to fuse. Leuk Res. 1997;21(10):997-9. (Pubitemid 27511407)
120. Kreitman RJ. Immunoconjugates and new molecular targets in hairy cell leukemia. Hematol/Educ Prog Am Soc Hemat Am Soc Hemat Educ Prog. 2012;2012:660-6. doi:10.1182/asheducation-2012.1.660.
121. Kreitman RJ, Tallman MS, Robak T, Coutre S, Wilson WH, Stetler-Stevenson M, et al. Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J Clin Oncol: Off J Am Soc Clin Oncol. 2012;30(15):1822-8. doi:10.1200/JCO.2011.38.1756.
122. .• Kreitman RJ, Stetler-Stevenson M, Margulies I, Noel P, Fitzgerald DJ, Wilson WH, et al. Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia. J Clin Oncol. 2009;27(18):2983-90. doi:10.1200/JCO.2008.20.2630. Study demonstrated the efficacy and safety of recombinant immunotoxins in relapsed refractory patients with HCL
123. Kreitman RJ, Wilson WH, White JD, Stetler-Stevenson M, Jaffe ES, Giardina S, et al. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol: Off J Am Soc Clin Oncol. 2000;18(8):1622-36. (Pubitemid 30220540)
124. Arons E, Stetler-Stevenson M, Wilson WH, FitzGerald DJP, Pastan I. Pharmacokinetic Analysis Of Response In Hairy Cell Leukemia Treated By Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox. Blood. 2013;122(21):2871.
125. Fowler N, Davis E. Targeting B-cell receptor signaling: changing the paradigm. Hematol/Educ Prog Am Soc Hematol Ame Soc Hematol Educ Prog. 2013;2013:553-60. doi:10.1182/asheducation-2013.1.553.
126. Jones JA, Kraut EH, Deam D, Byrd JC, Grever MR. Hematologic improvement after flavopiridol treatment of pentostatin and rituximab refractory hairy cell leukemia. Leuk Lymphoma. 2012;53(3):490-1. doi:10.3109/10428194.2011.600484.
127. Magee MJ, McKenzie S, Filippa DA, Arlin ZA, Gee TS, Clarkson BD. Hairy cell leukemia. Durability of response to splenectomy in 26 patients and treatment of relapse with androgens in six patients. Cancer. 1985;56(11):2557-62. (Pubitemid 16249913)
128. Golomb HM, Vardiman JW. Response to splenectomy in 65 patients with hairy cell leukemia: an evaluation of spleen weight and bone marrow involvement. Blood. 1983;61(2):349-52. (Pubitemid 13137656)
129. Kampmeier P, Spielberger R, Dickstein J, Mick R, Golomb H, Vardiman JW. Increased incidence of second neoplasms in patients treated with interferon alpha 2b for hairy cell leukemia: a clinicopathologic assessment. Blood. 1994;83(10):2931-8. (Pubitemid 24142726)
130. Zinzani PL, Bonifazi F, Pellegrini C, Casadei B, Argnani L, Motta MR, et al. Hairy cell leukemia: allogeneic transplantation could be an optimal option in selected patients. Clin Lymphoma Myeloma Leuk. 2012;12(4):287-9. doi:10.1016/j.clml.2012.05.001.
131. Maloisel F, Benboubker L, Gardembas M, Coiffier B, Divine M, Sebban C, et al. Long-term outcome with pentostatin treatment in hairy cell leukemia patients. A French retrospective study of 238 patients. Leukemia. 2003;17(1):45-51. (Pubitemid 36175887)